False Claims Act & Qui Tam
- Learn More
False Claims Act (FCA) investigations and litigation can be among the most consequential matters faced by companies and their boards. Paul, Weiss has successfully represented a wide range of clients in FCA and other matters involving allegations of government fraud. Our team offers an unparalleled combination of litigation expertise and senior government experience.
Randy Luskey Publishes Article on Pharma Speaker Programs Amid Increased FCA Scrutiny in Corporate Compliance Insights
June 7, 2023
Litigation partner Randy Luskey wrote an article in Corporate Compliance Insights on what pharmaceutical companies can do to minimize False Claims Act litigation risks around their speaker programs, which are used to educate health care professionals about pharmaceutical products. In “Hard Pill to Swallow: Sorting Out Conflicting Guidance for Pharma Speaker Programs,” published on June 7, Randy discusses increased government scrutiny of and FCA litigation over speaker programs; examines recent government and industry guidance on pharmaceutical speaker programs; and offers insights to help companies develop effective guardrails at a time when guidance is inconsistent and at times, ambiguous.
“Given the current scrutiny on speaker programs, it is more important than ever that pharmaceutical companies carefully plan such events with an eye toward compliance,” Randy writes. “While the current guidance is, at times, amorphous and contradictory, focusing on legitimate educational interests and strengthening speaker program monitoring efforts remain critical ingredients to designing and running compliant programs that help mitigate the risk of litigation.”
Litigation associate Jenny Gilbert contributed to the article.
» read the article